Synta announces publication of Hsp90-inhibitor first patent application

Synta Pharmaceuticals announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor Drug Conjugate platform. The patent application covers Synta's proprietary HDC technology, including composition of matter claims covering over 400 HDC compounds synthesized by Synta to date, methods for identifying therapeutically effective compounds, and methods of use against a wide range of diseases and conditions.